Percutaneous treatment of thrombosed primary arteriovenous hemodialysis access fistulae

Haage, Patrick; Vorwerk, Dierk; Wildberger, Joachim E.; Piroth, Werner; Schürmann, K.; Günther, Rolf W.

doi:10.1046/j.1523-1755.2000.00944.x

Cited by 126 publications

(81 citation statements)

References 23 publications

(2 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our study shows that after PTA, primary and secondary patency rates were similar to the outcomes observed by previous studies on upper limb hemodialysis access (Table 2) (12,(14)(15)(16)(17). Therefore, PTA is an effective treatment for dysfunctional femoral AV graft, as it is for the upper limb AV graft.…”

Section: Discussionsupporting

confidence: 89%

Percutaneous transluminal angioplasty for dysfunctional femoral hemodialysis graft

Kim²,

Goo³

et al. 2015

Diagn Interv Radiol

View full text Add to dashboard Cite

ORIGINAL ARTICLE PURPOSE We aimed to evaluate the safety and effectiveness of percutaneous transluminal angioplasty (PTA) for dysfunctional femoral arteriovenous graft and analyze clinical or anatomic predictors of graft patency. METHODSThe records of 45 patients who underwent PTA or thromboaspiration for dysfunctional or thrombosed femoral arteriovenous graft from 2005 to 2012 were reviewed retrospectively. Primary and secondary patency rates were determined at three, six, and 12 months after PTA. The primary patency rate was analyzed according to the presence of diabetes mellitus, graft age from the time of creation to the first intervention (<12 months or ≥12 months), presence of thrombus, shape of graft (U-shape vs. straight-shape), anastomosis type of graft (femoral-femoral vs. femoral-saphenous), location of stenosis (central vs. peripheral), length of stenosis (<2 cm vs. ≥2 cm), degree of stenosis severity (<70% vs. ≥70%), and stent insertion. RESULTSA total of 124 PTAs were performed in 45 patients. The primary patency rate at three, six, and 12 months was 84.8%, 63.6%, and 24.2%, respectively. The secondary patency rate at three, six, and 12 months was 95.2%, 95.2%, and 85.7%, respectively. The mean duration of primary and secondary patency was 13.2 and 35.7 months, respectively. No significant clinical or anatomical predictors of primary patency could be identified. Stent placement had a negative effect on primary patency. CONCLUSION PTA is a safe and effective treatment for dysfunctional femoral arteriovenous grafts. Stent placement seems to improve technical success, but does not enhance the primary patency rate of dysfunctional femoral arteriovenous grafts.

show abstract

Section: Discussionsupporting

confidence: 89%

Percutaneous transluminal angioplasty for dysfunctional femoral hemodialysis graft

Kim²,

Goo³

et al. 2015

Diagn Interv Radiol

View full text Add to dashboard Cite

show abstract

“…It has been shown that the long-term clinical effects after endovascular treatment of obstructive AVF lesions have improved over the past years, and are parallel with our own observations [17,19,[25][26][27][28]. It may be related to the availability of low profile, high pressure balloons and growing experience of interventional teams.…”

Section: Pawel Maga Et Al Endovascular Treatment Of Arteriovenous Fsupporting

confidence: 71%

Endovascular treatment of dysfunctional arteriovenous fistula in hemodialyzed patients — the results of one year follow-up

Maga

Krzanowski²,

Kaczmarczyk³

et al. 2017

Acta Angiologica

View full text Add to dashboard Cite

show abstract

“…Early studies reported relatively poor results with the treatment of thrombosed fistulae [5]. However, recent reports have documented excellent success [7][8][9]. Success in the treatment of thrombosed fistulae has ranged from 88 to 94% in these recent reports.…”

Section: Policies and Proceduresmentioning

confidence: 99%

Integrated Vascular Access Management

Beathard¹

2003

Blood Purif

View full text Add to dashboard Cite

Nephrologists need to deal with the problem of vascular access management in the same manner as the other major problems that affect our dialysis patients. We need to become experts in vascular access and we need to occupy a pivotal position in directing the decisions that are made that affect dialysis patient welfare. An integrated vascular access management strategy is required. Optimally, there should be four components to this strategy – evidence-based policies and procedures, a dedicated vascular access facility, committed vascular access surgeons and the availability of committed vascular access interventionalists. In many respects this is the approach that offers the best in quality of patient care and is also the most economic to deliver.

show abstract

Percutaneous treatment of thrombosed primary arteriovenous hemodialysis access fistulae

Cited by 126 publications

References 23 publications

Percutaneous transluminal angioplasty for dysfunctional femoral hemodialysis graft

Percutaneous transluminal angioplasty for dysfunctional femoral hemodialysis graft

Endovascular treatment of dysfunctional arteriovenous fistula in hemodialyzed patients — the results of one year follow-up

Integrated Vascular Access Management

Contact Info

Product

Resources

About